Assessment of bacille Calmette-Guérin vaccine reaction in HIV-exposed Thai infants

Clinical Infectious Diseases

Volumn 45, Issue 8, 2007, Pages 1016-1018

  Chokephaibulkit, Kulkanya ^a   Chotpitayasunondh, Tawee ^b   Vanprapar, Nirun ^a   Waranawat, Naris ^b   Mock, Philip A ^c   McConnell, Michelle S ^c,d   Jetswang, Bongkoch ^c   Neeyapun, Kanchana ^a   Tappero, Jordan W ^c,d   Culnane, Mary ^c,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^c Centers for Disease Control CDC Thailand Field Station   (Thailand)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; VACCINATION REACTION; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY; MYCOBACTERIUM BOVIS; NEWBORN; SCAR; THAILAND; TUBERCULOSIS;

CICATRIX; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MYCOBACTERIUM BOVIS; THAILAND; TUBERCULOSIS;

EID: 34848830809     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521929     Document Type: Article

References (21)

1. World Health Organization. Expanded program for immunization: program report. Geneva: World Health Organization, 1992.
2. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80.
3. Sirinavin S, Chotpitayasunondh T, Suwanjutha S, Sunakorn P, Chantarojanasiri T. Protective efficacy of neonatal bacillus Calmette-Guérin vaccination against tuberculosis. Pediatr Infect Dis J 1991; 10:359-65.
4. Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005; 366:1443-51.
5. Hoft DF, Leonardi C, Milligan T, et al. Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination. Clin Infect Dis 1999; 28:785-90.
6. Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis 1996; 174:113-9.
7. Deeks SL, Clark M, Scheifele DW, et al. Serious adverse events associated with bacille Calmette-Guérin vaccine in Canada. Pediatr Infect Dis J 2005; 24:538-41.
8. Gonzalez B, Moreno S, Burdach R, et al. Clinical presentation of bacillus Calmette-Guérin infections in patients with immunodeficiency syndromes. Pediatr Infect Dis J 1989; 8:201-6.
9. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006; 42:548-58.
10. Hesseling AC, Schaaf HS, Hanekom WA, et al. Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 2003; 37:1226-33.
11. Rosenfeldt V, Paerregaard A, Valerius NH. Disseminated infection with bacillus Calmette-Guérin in a child with advanced HIV disease. Scand J Infect Dis 1997; 29:526-7.
12. Lallemant-Le Coeur S, Lallemant M, Cheynier D, Nzingoula S, Drucker J, Larouze B. Bacillus Calmette-Guérin immunization in infants born to HIV-1-seropositive mothers. AIDS 1991; 5:195-9.
13. Weltman AC, Rose DN. The safety of bacille Calmette-Guérin vaccination in HIV infection and AIDS. AIDS 1993; 7:149-57.
14. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course ZDV for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353:773-80.
15. Chalermchokcharoenkit A, Asavapiriyanont S, Teeraratkul A, et al. Combination short-course zidovudine plus 2-dose nevirapine for prevention of mother-to-child transmission: safety, tolerance, transmission, and resistance results [abstract 96]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisoc, CA). 2004:111.
16. Teeraratkul A, Simonds RJ, Asavapiriyanont S, et al. Evaluating programs to prevent mother-to-child HIV transmission in two large Bangkok hospitals. JAIDS 2005; 38:208-12.
17. Centers for Disease Control and Prevention. BCG vaccination and pediatric HIV infection - Rwanda, 1988-1990. MMWR Morb Mortal Wkly Rep 1991; 40:833-6.
18. Watanaveeradej V, Samakoses R, Kerdpanich A. BCG scar response in infants of mothers infected with human immunodeficiency virus. Thai J Pediatr 2000; 39:107-14. Available at: http://www.thaipediatrics.org. Accesssed 31 August 2007.
19. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-8.
20. O'Brien KL, Ruff AJ, Louis MA, et al. Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995; 95:414-8.
21. World Health Organization. Revised BCG vaccination guidelines for infants at risk of HIV infection. Wkly Epidemiol Rec 2007; 82:181-96.